de la Cruz-Merino, Luis
Di Guardo, Lorenza
Grob, Jean-Jacques
Venosa, Alfredo
Larkin, James
McArthur, Grant A.
Ribas, Antoni
Ascierto, Paolo A.
Evans, Jeffrey T. R.
Gomez-Escobar, Antonio
Barteselli, Giulio
Eng, Susan
Hsu, Jessie J.
Uyei, Anne
Dréno, Brigitte
Clinical trials referenced in this document:
Documents that mention this clinical trial
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
https://doi.org/10.1186/s12967-020-02458-x
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
https://doi.org/10.1186/s12967-017-1246-0
MEK1/2 inhibitors in the treatment of gynecologic malignancies
https://doi.org/10.1016/j.ygyno.2014.01.008
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 24 March 2017
Accepted: 15 June 2017
First Online: 24 June 2017